6533b828fe1ef96bd1288ca1

RESEARCH PRODUCT

ChemInform Abstract: Mucin Glycopeptide-Protein Conjugates - Promising Antitumor Vaccine Candidates

subject

description

Recent efforts towards the development of synthetic glycopeptide vaccines, which aim at the active immunization of patients against their own tumor tissues, are outlined. To achieve sufficient tumor selectivity, glycopeptides of the tandem repeat region of tumor-associated mucin, MUC1, have been synthesized. Since the endogenous structures usually exert low immunogenicity, these glycopeptide antigens, as B-cell epitopes, were conjugated with immunostimulating components. In the present short review, work is outlined in which the MUC1 B-cell epitope peptides are conjugated with bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or tetanus toxoid (TTox). In particular, the synthetic vaccines based on tetanus toxoid induce very strong tolerance-breaking immune responses in mice. The induced antibodies of the IgG type indicate the installation of an immunological memory. In addition, these antibodies strongly bind to human breast tumor cells in culture, demonstrated by flow cytometry experiments, and also to the tumor cells in mammary carcinoma tissues.